The facility is expected to be fully operational by the end of next year, creating more than one hundred jobs and supporting the development of BioNTech’s portfolio of mRNA-based vaccines and therapeutics on a clinical and advertising scale.
Dr. Sierk Poetting, Chief Operating Officer of BioNTech, said: “We are excited to take a step towards expanding our global production network in Singapore, supporting the production of mRNA-based vaccines and treatments for the Asia-Pacific region.
“This acquisition provides us with the opportunity to boost the status quo of an mRNA production facility and thereby drive the creation of functions for prospective clinical studies and the source of publicity for our vaccines and mRNA-based therapies for the region.
“In the coming months, we will be working intensively with all parties on the elegant transition of the project as we continue to prepare for the launch. “
BioNTech’s mRNA facility in Singapore will create regional production functions for vaccines and mRNA-based treatments in the Asia-Pacific region, with the prospect of expanding production to other drug categories, such as mobile treatments.
First, the facility will be supplied to manufacture a variety of applicants for mRNA-based products, as well as vaccines and legal remedies for infectious diseases.
This may only come with the Pfizer/BioNTech COVID-19 vaccine, as well as long-term oncology product candidates.
It is expected to create more than one hundred jobs in Singapore through 2024 for purposes including operations, engineering, quality, finance, human resources, as well as supply chain management, and recruitment will begin without delay for the top positions.
The plant, acquired from Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd and supported through the Singapore Economic Development Board, will be owned by BioNTech’s subsidiary, BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. et, and will be fully incorporated into the company’s global production network.
The Singapore Economic Development Board said BioNTech’s investment in Singapore demonstrates “confidence in the deep production skills and capabilities base” of the biopharmaceutical ecosystem.
Sanofi is structuring a new $475 million vaccine facility in Singapore, while Merck announced earlier this year that it would invest $500 million to load biologics and vaccine functions into its production facility. In July, WuXi Biologics announced the structure of a CRDMO center in Singapore.
More promotional features